Elevated levels of serum prolactin in patients with advanced multiple myeloma

Klára Gadó, Éva Rimanóczi, Ágnes Hasitz, Gábor Gigler, B. Tóth, György M. Nagy, K. Pálóczi, Gyula Domján

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and Objective: The role of prolactin in immunoregulation and normal hemopoiesis is well known. However, prolactin also seems to be involved in the pathomechanism of malignancies and autoimmune diseases. Elevated serum prolactin levels were reported in patients with malignant lymphoma, colon and breast carcinoma, systemic lupus erythematosus and rheumatoid arthritis. Recently we demonstrated prolactin immunostaining in bone marrow cells of patients with multiple myeloma. Design and Methods: Serum prolactin levels of 56 patients with multiple myeloma, as well as serum β2-microglobulin, and interleukin-6 concentrations were determined in this study. Results: Patients with advanced disease showed a significant increase in serum prolactin concentration, while patients with a clinical stage of I and II, and also control patients had normal values. The concentration of serum β2-microglobulin and interleukin-6 changed in parallel with that of serum prolactin in patients with multiple myeloma. Determining serum prolactin levels several times during the disease process in a given patient clearly showed that the prolactin concentration was increasing during the disease progression. Interpretation and Conclusions: Our results indicate a role of prolactin in disease progression in multiple myeloma.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalNeuroImmunoModulation
Volume9
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Multiple Myeloma
Prolactin
Serum
Disease Progression
Interleukin-6
Bone Marrow Cells
Systemic Lupus Erythematosus
Autoimmune Diseases
Lymphoma
Rheumatoid Arthritis
Colon
Reference Values
Breast Neoplasms

Keywords

  • β-Microglobulin
  • Interleukin-6
  • Multiple myeloma
  • Prolactin

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Immunology

Cite this

Gadó, K., Rimanóczi, É., Hasitz, Á., Gigler, G., Tóth, B., Nagy, G. M., ... Domján, G. (2001). Elevated levels of serum prolactin in patients with advanced multiple myeloma. NeuroImmunoModulation, 9(4), 231-236. https://doi.org/10.1159/000049031

Elevated levels of serum prolactin in patients with advanced multiple myeloma. / Gadó, Klára; Rimanóczi, Éva; Hasitz, Ágnes; Gigler, Gábor; Tóth, B.; Nagy, György M.; Pálóczi, K.; Domján, Gyula.

In: NeuroImmunoModulation, Vol. 9, No. 4, 2001, p. 231-236.

Research output: Contribution to journalArticle

Gadó, K, Rimanóczi, É, Hasitz, Á, Gigler, G, Tóth, B, Nagy, GM, Pálóczi, K & Domján, G 2001, 'Elevated levels of serum prolactin in patients with advanced multiple myeloma', NeuroImmunoModulation, vol. 9, no. 4, pp. 231-236. https://doi.org/10.1159/000049031
Gadó, Klára ; Rimanóczi, Éva ; Hasitz, Ágnes ; Gigler, Gábor ; Tóth, B. ; Nagy, György M. ; Pálóczi, K. ; Domján, Gyula. / Elevated levels of serum prolactin in patients with advanced multiple myeloma. In: NeuroImmunoModulation. 2001 ; Vol. 9, No. 4. pp. 231-236.
@article{b5430c201ba24c53a96fa006fa4f1644,
title = "Elevated levels of serum prolactin in patients with advanced multiple myeloma",
abstract = "Background and Objective: The role of prolactin in immunoregulation and normal hemopoiesis is well known. However, prolactin also seems to be involved in the pathomechanism of malignancies and autoimmune diseases. Elevated serum prolactin levels were reported in patients with malignant lymphoma, colon and breast carcinoma, systemic lupus erythematosus and rheumatoid arthritis. Recently we demonstrated prolactin immunostaining in bone marrow cells of patients with multiple myeloma. Design and Methods: Serum prolactin levels of 56 patients with multiple myeloma, as well as serum β2-microglobulin, and interleukin-6 concentrations were determined in this study. Results: Patients with advanced disease showed a significant increase in serum prolactin concentration, while patients with a clinical stage of I and II, and also control patients had normal values. The concentration of serum β2-microglobulin and interleukin-6 changed in parallel with that of serum prolactin in patients with multiple myeloma. Determining serum prolactin levels several times during the disease process in a given patient clearly showed that the prolactin concentration was increasing during the disease progression. Interpretation and Conclusions: Our results indicate a role of prolactin in disease progression in multiple myeloma.",
keywords = "β-Microglobulin, Interleukin-6, Multiple myeloma, Prolactin",
author = "Kl{\'a}ra Gad{\'o} and {\'E}va Riman{\'o}czi and {\'A}gnes Hasitz and G{\'a}bor Gigler and B. T{\'o}th and Nagy, {Gy{\"o}rgy M.} and K. P{\'a}l{\'o}czi and Gyula Domj{\'a}n",
year = "2001",
doi = "10.1159/000049031",
language = "English",
volume = "9",
pages = "231--236",
journal = "NeuroImmunoModulation",
issn = "1021-7401",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Elevated levels of serum prolactin in patients with advanced multiple myeloma

AU - Gadó, Klára

AU - Rimanóczi, Éva

AU - Hasitz, Ágnes

AU - Gigler, Gábor

AU - Tóth, B.

AU - Nagy, György M.

AU - Pálóczi, K.

AU - Domján, Gyula

PY - 2001

Y1 - 2001

N2 - Background and Objective: The role of prolactin in immunoregulation and normal hemopoiesis is well known. However, prolactin also seems to be involved in the pathomechanism of malignancies and autoimmune diseases. Elevated serum prolactin levels were reported in patients with malignant lymphoma, colon and breast carcinoma, systemic lupus erythematosus and rheumatoid arthritis. Recently we demonstrated prolactin immunostaining in bone marrow cells of patients with multiple myeloma. Design and Methods: Serum prolactin levels of 56 patients with multiple myeloma, as well as serum β2-microglobulin, and interleukin-6 concentrations were determined in this study. Results: Patients with advanced disease showed a significant increase in serum prolactin concentration, while patients with a clinical stage of I and II, and also control patients had normal values. The concentration of serum β2-microglobulin and interleukin-6 changed in parallel with that of serum prolactin in patients with multiple myeloma. Determining serum prolactin levels several times during the disease process in a given patient clearly showed that the prolactin concentration was increasing during the disease progression. Interpretation and Conclusions: Our results indicate a role of prolactin in disease progression in multiple myeloma.

AB - Background and Objective: The role of prolactin in immunoregulation and normal hemopoiesis is well known. However, prolactin also seems to be involved in the pathomechanism of malignancies and autoimmune diseases. Elevated serum prolactin levels were reported in patients with malignant lymphoma, colon and breast carcinoma, systemic lupus erythematosus and rheumatoid arthritis. Recently we demonstrated prolactin immunostaining in bone marrow cells of patients with multiple myeloma. Design and Methods: Serum prolactin levels of 56 patients with multiple myeloma, as well as serum β2-microglobulin, and interleukin-6 concentrations were determined in this study. Results: Patients with advanced disease showed a significant increase in serum prolactin concentration, while patients with a clinical stage of I and II, and also control patients had normal values. The concentration of serum β2-microglobulin and interleukin-6 changed in parallel with that of serum prolactin in patients with multiple myeloma. Determining serum prolactin levels several times during the disease process in a given patient clearly showed that the prolactin concentration was increasing during the disease progression. Interpretation and Conclusions: Our results indicate a role of prolactin in disease progression in multiple myeloma.

KW - β-Microglobulin

KW - Interleukin-6

KW - Multiple myeloma

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0035719629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035719629&partnerID=8YFLogxK

U2 - 10.1159/000049031

DO - 10.1159/000049031

M3 - Article

C2 - 11847486

AN - SCOPUS:0035719629

VL - 9

SP - 231

EP - 236

JO - NeuroImmunoModulation

JF - NeuroImmunoModulation

SN - 1021-7401

IS - 4

ER -